Search Results

Deals

Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the acquisition of Cavion, Inc. through a merger with a Jazz subsidiary.

August 12, 2019

·

7 min read

Drug Development

Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial

Cavion’s Results to be Featured as Late Breaker at International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong

October 4, 2018

·

4 min read

Business

Cavion Appoints Julia P. Gregory Executive Chair

Julia Gregory Brings to Cavion a Wealth of Experience and Deep Expertise in the Biopharma Industry

September 11, 2018

·

2 min read

BioCapital

Cavion to Present Data Highlighting Company’s Pipeline in Neurological Disorders at 70th American Academy of Neurology (AAN) Annual Meeting

Cavion, Inc. will present clinical and preclinical data on the company’s lead compound, the potent Cav3 antagonist CX-8998, at the Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, April 21-27.

April 19, 2018

·

4 min read

BioCapital

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model

Data to be Presented in Poster at the Society for Neuroscience Annual Meeting

November 5, 2018

·

4 min read

Drug Development

Cavion to Present Results of Phase 2 Essential Tremor Clinical Trial in Platform Presentation at the American Academy of Neurology

Presentation to provide overview of Phase 2 T-CALM study design, results and clinical path forward

April 24, 2019

·

3 min read

Drug Development

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study

Totality of Data Demonstrates CX-8998 is Well Tolerated with Compelling Evidence of Efficacy Despite Missing Primary Endpoint Measured Using Central Video Rating

October 5, 2018

·

7 min read

Drug Development

First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy

Study to investigate new therapeutic approach for generalized epilepsy with absence seizures

March 20, 2018

·

4 min read

BioCapital

Cavion To Present Clinical Trial Preliminary Results At ASTRO

September 26, 2016

·

1 min read

Business

Struggling Teva Loses Top R&D Exec To Eli Lilly, Novartis AG-Backed Cavion

August 15, 2017

·

2 min read